WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

REVIEW ON BEDAQUILINE: A NEW FDA APPROVED DRUG FOR MULTI-DRUG RESISTANT TUBERCULOSIS

Keerthana Kripa R. R., Gopika B., *Renuka R. and Dr. Elessy Abraham

ABSTRACT

Tuberculosis (TB) is a communicable infectious disease caused by Mycobacterium tuberculosis that can affect almost any part of the body but it is mainly an infection of lungs. It can produce silent, latent infection, as well as progressive, active disease. The challenging area is its management since patient develops drug resistant TB and with coexisting HIV. Patients with MDR-TB that is difficult to treat, such as pre-XDR-TB and XDR-TB, or intolerance to older drugs, need better options as soon as possible. Despite the rise in incidence of MDR-TB worldwide over the past few decades, no TB specific drug has been discovered in last 40 years. Emergence of some new anti-tubercular drugs is a scope as they promise high efficiency and shortens the duration of treatment. After such a long waiting period, revival in research and development activity in this area has resulted in discovery of a new anti-tubercular drug Bedaquiline/TMC207. It should be used as a part of an appropriate combination regimen for pulmonary MDR-TB in adult patients in whom the current approved regimen cannot be used because of resistance or intolerability. The emergence of this new drug can improve treatment status of TB and thus a hope for the better control of the disease.

Keywords: Mycobacterium, Anti-Tubercular drugs, Bedaquiline, MDR- TB.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More